William Blair equity research analyst Sami Corwin was quoted in BioSpace’s coverage of a new, though debated, rare disease framework announced by the FDA in September.

“It remains unclear what tangible impact the framework will have on the development process and approval timeline, given several gene therapies in development are already utilizing single-arm trials for registration,” Corwin wrote in a note to investors that was cited by the publication.